Treats hypertension. Sold as Lotensin. Every FDA application for this active ingredient: 1 branded and 12 generic.
As of Nov 15, 2026, FDA lists 13 applications for Benazepril Hydrochloride (sold as Lotensin), first approved Jun 25, 1991, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Benazepril HCl | Part D | $20.9M | -6% | 507,019 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Bioequivalence Study of Sacubitril Alisartan Amlodipine TabletsPrimary Hypertension · Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 1 | Not yet recruiting | Mar 20, 2026 |
| Jun 25, 1991 | LotensinNDA 19851 · New molecular entity | Validus Pharms | 44 | Marketed |
| Feb 11, 2004 | Benazepril HydrochlorideANDA 76118 | Prinston Inc | 10 | Marketed |
| Feb 11, 2004 | Benazepril HydrochlorideANDA 76211 | Teva | 14 | Marketed |
| Feb 11, 2004 | Benazepril HydrochlorideANDA 76267 | Heritage Pharma | 2 | Marketed |
| Feb 11, 2004 | Benazepril HydrochlorideANDA 76333 | Ani Pharms | 2 | Marketed |
| Feb 11, 2004 | Benazepril HydrochlorideANDA 76344 | Sun Pharm Inds Ltd | 9 | Marketed |
| Feb 11, 2004 | Benazepril HydrochlorideANDA 76402 | Chartwell Rx | 9 | Marketed |
| Feb 11, 2004 | Benazepril HydrochlorideANDA 76430 | Rising | 8 | Discontinued |
| Feb 11, 2004 | Benazepril HydrochlorideANDA 76476 | Genpharm | 0 | Discontinued |
| Feb 3, 2006 | Benazepril HydrochlorideANDA 76820 | Amneal Pharms | 9 | Marketed |
| Mar 8, 2006 | Benazepril HydrochlorideANDA 77128 | Macleods Pharms | 11 | Marketed |
| May 22, 2008 | Benazepril HydrochlorideANDA 78212 | Aurobindo Pharma | 13 | Marketed |
| May 23, 2008 | Benazepril HydrochlorideANDA 78848 | Zydus Lifesciences | 4 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA